source
- FDA launches rare disease framework initiativeA new initiative from the US Food and Drug Administration (FDA) aims to develop “an optimized, fit-for-purpose” framework to facilitate the development and marketing of treatments for rare diseases…raps · 6d ago↗ source
- Verastem reports promising early results for KRAS G12D inhibitor in pancreatic and lung cancersVerastem Oncology has shifted its research toward a KRAS G12D inhibitor, VS-7375, and released early data from a phase 1/2 study involving more than 200 patients with advanced KRAS G12D-mutated sol…